S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)

CEL-SCI Stock Forecast, Price & News

+0.51 (+8.36%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.04 million shs
Average Volume
597,430 shs
Market Capitalization
$285.84 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CVM News and Ratings via Email

Sign-up to receive the latest news and ratings for CEL-SCI and its competitors with MarketBeat's FREE daily newsletter.

CEL-SCI logo


CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.


See More Headlines

Industry, Sector and Symbol

Stock Exchange
Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$560 thousand
Book Value
$1.31 per share


Net Income
$-36.36 million
Pretax Margin




Free Float
Market Cap
$285.84 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.18 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

CEL-SCI (NYSEAMERICAN:CVM) Frequently Asked Questions

How has CEL-SCI's stock been impacted by COVID-19 (Coronavirus)?

CEL-SCI's stock was trading at $9.74 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CVM stock has decreased by 32.1% and is now trading at $6.61.
View which stocks have been most impacted by COVID-19

When is CEL-SCI's next earnings date?

CEL-SCI is scheduled to release its next quarterly earnings announcement on Monday, February 14th 2022.
View our earnings forecast for CEL-SCI

How were CEL-SCI's earnings last quarter?

CEL-SCI Co. (NYSEAMERICAN:CVM) posted its quarterly earnings results on Wednesday, December, 22nd. The company reported ($0.19) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.09.
View CEL-SCI's earnings history

When did CEL-SCI's stock split? How did CEL-SCI's stock split work?

Shares of CEL-SCI reverse split on Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 14th 2017. An investor that had 100 shares of CEL-SCI stock prior to the reverse split would have 4 shares after the split.

Who are CEL-SCI's key executives?

CEL-SCI's management team includes the following people:
  • Geert R. Kersten, CEO, Chief Financial Officer, Treasurer & Director
  • Patricia B. Prichep, Secretary & Senior Vice President-Operations
  • Eyal Talor, Chief Scientific Officer
  • William Jones, Vice President-Quality Assurance
  • Daniel H. Zimmerman, Senior VP-Research & Cellular Immunology

What other stocks do shareholders of CEL-SCI own?

What is CEL-SCI's stock symbol?

CEL-SCI trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVM."

Who are CEL-SCI's major shareholders?

CEL-SCI's stock is owned by a number of retail and institutional investors. Top institutional investors include Calton & Associates Inc. (0.05%). Company insiders that own CEL-SCI stock include Eyal Talor, Geert R Kersten, John Cipriano, Patricia B Prichep, Peter R Young and Robert Eugene Watson.
View institutional ownership trends for CEL-SCI

Which major investors are selling CEL-SCI stock?

CVM stock was sold by a variety of institutional investors in the last quarter, including Calton & Associates Inc.. Company insiders that have sold CEL-SCI company stock in the last year include Eyal Talor, and John Cipriano.
View insider buying and selling activity for CEL-SCI
or view top insider-selling stocks.

How do I buy shares of CEL-SCI?

Shares of CVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CEL-SCI's stock price today?

One share of CVM stock can currently be purchased for approximately $6.61.

How much money does CEL-SCI make?

CEL-SCI has a market capitalization of $285.84 million and generates $560 thousand in revenue each year. The company earns $-36.36 million in net income (profit) each year or ($0.93) on an earnings per share basis.

How many employees does CEL-SCI have?

CEL-SCI employs 2,020 workers across the globe.

What is CEL-SCI's official website?

The official website for CEL-SCI is www.cel-sci.com.

Where are CEL-SCI's headquarters?

How can I contact CEL-SCI?

CEL-SCI's mailing address is 8229 Boone Blvd Ste 802, VIENNA, VA 22182-2634, United States. The company can be reached via phone at (703) 506-9460, via email at [email protected], or via fax at 703-506-9471.

This page was last updated on 1/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.